Synthesis, in vitro and in silico screening of 2-amino-4-aryl-6-(phenylthio) pyridine-3,5-dicarbonitriles as novel ? -glucosidase inhibitors

被引:31
作者
Ali, Muhammad [1 ]
Khan, Khalid Mohammed [1 ,2 ,3 ]
Mahdavi, Mohammad [4 ]
Jabbar, Abdul [5 ]
Shamim, Shahbaz [1 ]
Salar, Uzma [6 ]
Taha, Muhammad [3 ]
Perveen, Shahnaz [7 ]
Larijani, Bagher [4 ]
Faramarzi, Mohammad Ali [8 ]
机构
[1] Univ Karachi, Int Ctr Chem & Biol Sci, HEJ Res Inst Chem, Karachi 75270, Pakistan
[2] Pakistan Acad Sci, 3 Constitut Ave G-5-2, Islamabad, Pakistan
[3] Imam Abdulrahman Bin Faisal Univ, Inst Res & Med Consultat IRMC, Dept Clin Pharm, POB 31441, Dammam, Saudi Arabia
[4] Univ Tehran Med Sci, Endocrinol & Metab Res Inst EMRI, Tehran, Iran
[5] Univ Melbourne, Fac Vet & Agr Sci, Melbourne Vet Sch, Dept Vet Biosci, 250 Princes Highway, Werribee, Vic 250, Australia
[6] Univ Karachi, Int Ctr Chem & Biol Sci, Dr Panjwani Ctr Mol Med & Drug Res, Karachi 75270, Pakistan
[7] PCSIR Labs Complex, Karachi 75280, Pakistan
[8] Univ Tehran Med Sci, Fac Pharm, Dept Pharmaceut Biotechnol, Tehran, Iran
关键词
COMPARATIVE ANTIDIABETIC EVALUATION; HIGHLY FUNCTIONALIZED PYRIDINES; ALPHA-GLUCOSIDASE; ONE-POT; STRUCTURAL-CHARACTERIZATION; MULTICOMPONENT SYNTHESIS; 3-COMPONENT SYNTHESIS; DIFFERENT PARTS; SOLVENT-FREE; ONE-STEP;
D O I
10.1016/j.bioorg.2020.103879
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Inhibition of α-glucosidase enzyme is of prime importance for the treatment of diabetes mellitus (DM). Apart of many organic scaffolds, pyridine based compounds have previously been reported for wide range of bioactivities. The current study reports a series of pyridine based synthetic analogues for their α-glucosidase inhibitory potential assessed by in vitro, kinetics and in silico studies. For this purpose, 2-amino-4-aryl-6-(phenylthio)pyridine-3,5-dicarbonitriles 1–28 were synthesized and subjected to in vitro screening. Several analogs, including 1–3, 7, 9, 11–14, and 16 showed many folds increased inhibitory potential in comparison to the standard acarbose (IC50 = 750 ± 10 µM). Interestingly, compound 7 (IC50 = 55.6 ± 0.3 µM) exhibited thirteen-folds greater inhibition strength than the standard acarbose. Kinetic studies on most potent molecule 7 revealed a competitive type inhibitory mechanism. In silico studies have been performed to examine the binding mode of ligand (compound 7) with the active site residues of α-glucosidase enzyme. © 2020 Elsevier Inc.
引用
收藏
页数:13
相关论文
共 40 条
[1]  
Abbasi MA, 2017, J CHEM SOC PAKISTAN, V39, P248
[2]   New 6-amino-pyrido[2,3-d]pyrimidine-2,4-diones as novel agents to treat type 2 diabetes: A simple and efficient synthesis, α-glucosidase inhibition, molecular modeling and kinetic study [J].
Adib, Mehdi ;
Peytam, Fariba ;
Rahmanian-Jazi, Mahmoud ;
Mahernia, Shabnam ;
Bijanzadeh, Hamid Reza ;
Jahani, Mehdi ;
Mohammadi-Khanaposhtani, Maryam ;
Imanparast, Somaye ;
Faramarzi, Mohammad Ali ;
Mahdavi, Mohammad ;
Larijani, Bagher .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 155 :353-363
[3]  
Ahad G, 2018, J CHEM SOC PAKISTAN, V40, P961
[4]  
Ajaib M, 2016, J CHEM SOC PAKISTAN, V38, P1267
[5]  
Ajaib M, 2016, J CHEM SOC PAKISTAN, V38, P313
[6]   Hydrazinyl arylthiazole based pyridine scaffolds: Synthesis, structural characterization, in vitro α-glucosidase inhibitory activity, and in silico studies [J].
Ali, Farman ;
Khan, Khalid Mohammed ;
Salar, Uzma ;
Taha, Muhammad ;
Ismail, Nor Hadiani ;
Wadood, Abdul ;
Riaz, Muhammad ;
Perveen, Shahnaz .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 138 :255-272
[7]   Glycosidase inhibitors: update and perspectives on practical use [J].
Asano, N .
GLYCOBIOLOGY, 2003, 13 (10) :93R-104R
[8]   One-step, three-component synthesis of highly substituted pyridines using silica nanoparticle as reusable catalyst [J].
Banerjee, Subhash ;
Sereda, Grigoriy .
TETRAHEDRON LETTERS, 2009, 50 (50) :6959-6962
[9]   Using Oral Agents to Manage Gestational Diabetes: What Have We Learned? [J].
Buschur, Elizabeth ;
Brown, Florence ;
Wyckoff, Jennifer .
CURRENT DIABETES REPORTS, 2015, 15 (02)
[10]  
Chabrier P.E., 1988, CARDIOVASC DRUG REV, V6, P166, DOI 10.1111/j.1527-3466.1988.tb00518.x